Delayed Diagnosis of Bacteriologically Positive Pulmonary Tuberculosis and Relative Optimized Suggestions in China
Condition: Tuberculosis; Pulmonary, Confirmed, Unspecified Means Intervention: Sponsor: Huashan Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 17, 2020 Category: Research Source Type: clinical trials
Xpert MTB/RIF Test in the Diagnosis of Pulmonary Tuberculosis
Condition: Pulmonary Tuberculosis Confirmation by Culture Intervention: Diagnostic Test: Xpert MTB/RIF test Sponsors: Taipei Medical University WanFang Hospital; Buddhist Tzu Chi General Hospital; Chest Hospital, Ministry of Health and Welfare, Taiwan; Chang-Hua Hospital; Taichung Veterans General Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 16, 2020 Category: Research Source Type: clinical trials
Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation
Conditions: Latent Tuberculosis; Diabetes Mellitus, Type 2 Interventions: Drug: Rifampicin 300 Mg Oral Capsule; Drug: Isoniazid 300 MG Sponsor: Herlev and Gentofte Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 12, 2020 Category: Research Source Type: clinical trials
Safety and efficacy assessment of allogeneic human dental pulp stem cells to treat patients with severe COVID-19: structured summary of a study protocol for a randomized controlled trial (Phase I / II)
AbstractObjectivesTo assess the safety and therapeutic effects of allogeneic human dental pulp stem cells (DPSCs) in treating severe pneumonia caused by COVID-19.Trial designThis is a single centre, two arm ratio 1:1, triple blinded, randomized, placebo-controlled, parallel group, clinical trial.ParticipantsTwenty serious COVID-19 cases will be enrolled in the trial from April 6th to December 31st 2020. Inclusion Criteria: hospitalised patients at Renmin Hospital of Wuhan University satisfy all criteria as below:Adults aged 18-65 years;Voluntarily participate in this clinical trial and sign the “informed consent form...
Source: Trials - June 11, 2020 Category: Research Source Type: clinical trials
Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation
Conditions: Latent Tuberculosis; Diabetes Mellitus, Type 2 Interventions: Drug: Rifampicin 300 Mg Oral Capsule; Drug: Isoniazid 300 MG Sponsor: Herlev and Gentofte Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 11, 2020 Category: Research Source Type: clinical trials
Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China
Condition: Multidrug Resistant Tuberculosis Intervention: Drug: Delamanid Sponsor: Beijing Chest Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials
The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants
Conditions: HIV-1-infection; Tuberculosis Interventions: Drug: Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid; Drug: Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid; Drug: Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz Sponsors: Willem Daniel Francois Venter; University of Cape Town Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials
Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China
Condition: Multidrug Resistant Tuberculosis Intervention: Drug: Delamanid Sponsor: Beijing Chest Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials
The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants
Conditions: HIV-1-infection; Tuberculosis Interventions: Drug: Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid; Drug: Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid; Drug: Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz Sponsors: Willem Daniel Francois Venter; University of Cape Town Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials
Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China
Condition: Multidrug Resistant Tuberculosis Intervention: Drug: Delamanid Sponsor: Beijing Chest Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials
The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants
Conditions: HIV-1-infection; Tuberculosis Interventions: Drug: Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid; Drug: Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid; Drug: Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz Sponsors: Willem Daniel Francois Venter; University of Cape Town Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials
Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China
Condition: Multidrug Resistant Tuberculosis Intervention: Drug: Delamanid Sponsor: Beijing Chest Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials
The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants
Conditions: HIV-1-infection; Tuberculosis Interventions: Drug: Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid; Drug: Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid; Drug: Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz Sponsors: Willem Daniel Francois Venter; University of Cape Town Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials
Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China
Condition: Multidrug Resistant Tuberculosis Intervention: Drug: Delamanid Sponsor: Beijing Chest Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials
The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants
Conditions: HIV-1-infection; Tuberculosis Interventions: Drug: Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid; Drug: Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid; Drug: Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz Sponsors: Willem Daniel Francois Venter; University of Cape Town Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials
Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China
Condition: Multidrug Resistant Tuberculosis Intervention: Drug: Delamanid Sponsor: Beijing Chest Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials
The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants
Conditions: HIV-1-infection; Tuberculosis Interventions: Drug: Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid; Drug: Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid; Drug: Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz Sponsors: Willem Daniel Francois Venter; University of Cape Town Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials
Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China
Condition: Multidrug Resistant Tuberculosis Intervention: Drug: Delamanid Sponsor: Beijing Chest Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials
The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants
Conditions: HIV-1-infection; Tuberculosis Interventions: Drug: Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid; Drug: Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid; Drug: Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz Sponsors: Willem Daniel Francois Venter; University of Cape Town Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials
Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China
Condition: Multidrug Resistant Tuberculosis Intervention: Drug: Delamanid Sponsor: Beijing Chest Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials
The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants
Conditions: HIV-1-infection; Tuberculosis Interventions: Drug: Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid; Drug: Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid; Drug: Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz Sponsors: Willem Daniel Francois Venter; University of Cape Town Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2020 Category: Research Source Type: clinical trials
To Assess the Efficiency and Satisfaction of Pharmacist Giving Patient-centred Advice on Telephone Consultation in TB Patients: Experience of the COVID-19 Pandemic
Conditions: TB - Tuberculosis; Patient Satisfaction Intervention: Behavioral: Patient-centred advice on Telephone Consultation in TB Patients: Sponsors: Health Science Center of Xi’an Jiaotong University; Pakistan Institute of Medical Sciences Islamabad Pakistan; District Headquarter Hospital Bannu Pakistan Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 2, 2020 Category: Research Source Type: clinical trials
